Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Summary

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be accessible on November 25 via the company’s investor relations website. Halozyme focuses on innovative biopharmaceutical solutions, primarily using its proprietary ENHANZE® technology, which enhances drug delivery and has positively impacted over 400,000 patients globally. The company partners with major pharmaceutical firms to develop new therapies, enhancing patient experiences and outcomes.

SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside chat presentation for the Piper Sandler 32^nd Annual Virtual Healthcare Conference.  The virtual conference will be held from December 1-3, 2020.

The pre-recorded fireside chat will be available online Wednesday, November 25 in the investor relations section of the company's website at https://www.halozyme.com/investors/events-and-webcast/. 

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE^® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE^® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE^®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-fireside-chat-for-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301176413.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme be featured in the Piper Sandler Virtual Healthcare Conference?

Halozyme will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020.

What date will the pre-recorded fireside chat from Halozyme be available?

The pre-recorded fireside chat will be available on November 25, 2020.

Who is presenting for Halozyme at the conference?

Dr. Helen Torley, the president and CEO of Halozyme, will be presenting at the conference.

What is the significance of Halozyme's ENHANZE® technology?

ENHANZE® technology significantly reduces treatment times for patients, enhancing their overall experience.

How many patients have benefited from Halozyme's solutions?

Halozyme's solutions have positively impacted more than 400,000 patients worldwide.